JP2008536853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008536853A5 JP2008536853A5 JP2008506668A JP2008506668A JP2008536853A5 JP 2008536853 A5 JP2008536853 A5 JP 2008536853A5 JP 2008506668 A JP2008506668 A JP 2008506668A JP 2008506668 A JP2008506668 A JP 2008506668A JP 2008536853 A5 JP2008536853 A5 JP 2008536853A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- acceptable salt
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- VTPNIONIOLOGFM-UHFFFAOYSA-N 3-[2-[2-cyclopentyl-6-(4-dipropylphosphorylanilino)purin-9-yl]ethyl]phenol Chemical compound C1=CC(P(=O)(CCC)CCC)=CC=C1NC1=NC(C2CCCC2)=NC2=C1N=CN2CCC1=CC=CC(O)=C1 VTPNIONIOLOGFM-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 2
- 229960003736 bosutinib Drugs 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 2
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 claims 2
- 229950009919 saracatinib Drugs 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004214 philadelphia chromosome Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67074405P | 2005-04-13 | 2005-04-13 | |
| US74843305P | 2005-12-08 | 2005-12-08 | |
| US11/402,502 US20060235006A1 (en) | 2005-04-13 | 2006-04-12 | Combinations, methods and compositions for treating cancer |
| PCT/US2006/013773 WO2006113304A2 (en) | 2005-04-13 | 2006-04-13 | Combinations, methods and compositions for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008536853A JP2008536853A (ja) | 2008-09-11 |
| JP2008536853A5 true JP2008536853A5 (cg-RX-API-DMAC7.html) | 2009-05-28 |
Family
ID=37109315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008506668A Withdrawn JP2008536853A (ja) | 2005-04-13 | 2006-04-13 | 癌治療のための、組み合わせ、方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20060235006A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1868435A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008536853A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080004495A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006236812A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0608176A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2604581A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA200702238A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007012537A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20075087L (cg-RX-API-DMAC7.html) |
| TW (1) | TW200722091A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006113304A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2391550T3 (es) | 1999-04-15 | 2012-11-27 | Bristol-Myers Squibb Company | Inhibidores cíclicos de la proteína tirosina quinasa |
| DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
| US8247419B2 (en) * | 2005-06-09 | 2012-08-21 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant kit protein |
| PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
| US20090099197A1 (en) * | 2005-11-15 | 2009-04-16 | Bristol-Myers Squibb Company | Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof |
| BRPI0709749A2 (pt) * | 2006-04-05 | 2011-07-26 | Novartis Ag | combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer |
| AU2007235976A1 (en) * | 2006-04-07 | 2007-10-18 | Novartis Ag | Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |
| WO2008064004A2 (en) * | 2006-11-16 | 2008-05-29 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
| US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
| WO2008089135A2 (en) * | 2007-01-12 | 2008-07-24 | University Of South Florida | Identification of biomarkers predictive of dasatinib effects in cancer cells |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| WO2009076373A1 (en) * | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| ES2692769T3 (es) | 2008-06-17 | 2018-12-05 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| CN109464445A (zh) * | 2008-08-04 | 2019-03-15 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| EP2370175A2 (en) * | 2008-12-16 | 2011-10-05 | Bristol-Myers Squibb Company | Methods of inhibiting quiescent tumor proliferation |
| EP2769737B1 (en) * | 2009-07-20 | 2017-04-05 | Bristol-Myers Squibb Company | Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases |
| CA2775155A1 (en) * | 2009-10-01 | 2011-04-07 | Csl Limited | Method of treatment of philadelphia chromosome positive leukemia |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| ES2391550T3 (es) * | 1999-04-15 | 2012-11-27 | Bristol-Myers Squibb Company | Inhibidores cíclicos de la proteína tirosina quinasa |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US20040167134A1 (en) * | 2001-05-16 | 2004-08-26 | Christian Bruns | Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| US20040142888A1 (en) * | 2002-08-07 | 2004-07-22 | Veeraswamy Manne | Modulators of RabGGT and methods of use thereof |
| US20050009891A1 (en) * | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| AR047530A1 (es) * | 2004-02-04 | 2006-01-25 | Novartis Ag | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida |
| US7491725B2 (en) * | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
-
2006
- 2006-04-12 US US11/402,502 patent/US20060235006A1/en not_active Abandoned
- 2006-04-13 KR KR1020077023422A patent/KR20080004495A/ko not_active Withdrawn
- 2006-04-13 EP EP06749971A patent/EP1868435A4/en not_active Withdrawn
- 2006-04-13 WO PCT/US2006/013773 patent/WO2006113304A2/en not_active Ceased
- 2006-04-13 TW TW095113103A patent/TW200722091A/zh unknown
- 2006-04-13 EA EA200702238A patent/EA200702238A1/ru unknown
- 2006-04-13 BR BRPI0608176-2A patent/BRPI0608176A2/pt not_active IP Right Cessation
- 2006-04-13 AU AU2006236812A patent/AU2006236812A1/en not_active Abandoned
- 2006-04-13 JP JP2008506668A patent/JP2008536853A/ja not_active Withdrawn
- 2006-04-13 MX MX2007012537A patent/MX2007012537A/es not_active Application Discontinuation
- 2006-04-13 CA CA002604581A patent/CA2604581A1/en not_active Abandoned
-
2007
- 2007-10-09 NO NO20075087A patent/NO20075087L/no not_active Application Discontinuation
-
2008
- 2008-10-23 US US12/256,771 patent/US20090054415A1/en not_active Abandoned